Natera Inc NTRA
News
Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™
ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
Natera Reports Second Quarter 2026 Financial Results
Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
Natera to Report its Second Quarter Results on August 6, 2026
Natera Gets FDA Approval for Bladder-Cancer Test
